The Surgical Management of Migraines and Chronic Headaches A Cross-sectional Review of American Insurance Coverage

被引:2
作者
Zhu, Kevin [1 ]
Ha, Michael [1 ]
Finkelstein, Emily R. [2 ]
Chaudry, Salman [3 ]
Hricz, Nicholas [1 ]
Ngaage, Ledibabari M. [1 ,4 ]
Rasko, Yvonne [1 ,5 ]
机构
[1] Univ Maryland, Sch Med, Dept Surg, Div Plast Surg, Baltimore, MD USA
[2] Univ Miami, Div Plast & Reconstruct Surg, Miami, FL USA
[3] Anne Arundel Med Ctr, Dept Gen Surg, Annapolis, MD USA
[4] Univ Maryland, Johns Hopkins Hosp, Med Ctr, Dept Plast & Reconstruct Surg, Baltimore, MD USA
[5] 419 West Redwood St,Suite 300, Baltimore, MD 21201 USA
关键词
cross-sectional review; headache; insurance; migraine surgery; procedures; CORRUGATOR SUPERCILII MUSCLE; OCCIPITAL NEURALGIA; NERVE-STIMULATION; UNITED-STATES; ONABOTULINUMTOXINA; EFFICACY; EXCISION; OUTCOMES; SAFETY; ADULTS;
D O I
10.1097/SAP.0000000000003563
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundMigraine headache can be an extremely debilitating condition, with pharmacotherapy for prophylaxis or treatment of acute symptoms being unsuccessful in a large proportion of patients. Surgical management of migraine has recently gained popularity as an alternative to pharmacotherapy for severe disease. However, the novel nature of these procedures may lead to variable insurance coverage, limiting access to care.MethodsA cross-sectional analysis of 101 US insurance companies was conducted. Companies were chosen based on greatest market share and enrollment per state. A Web-based search or phone call identified whether each company had a publicly available policy on nonsurgical or surgical management of migraine or headache. For companies with an available policy, coverage was categorized into covered, covered on a case-by-case basis, or never covered, with criteria required for coverage collected and categorized.ResultsOf the 101 evaluated insurers, significantly fewer companies had a policy on surgical treatment for migraine or headache (n = 52 [52%]) compared with nonsurgical treatment (n = 78 [78%]) (P < 0.001). For companies with a policy, the most frequently covered nonsurgical treatments were biofeedback (n = 23 [92%]) and botulism toxin injections (n = 61 [88%]). Headaches were an approved indication for occipital nerve stimulation in 4% (n = 2) of company policies and nerve decompression in 2% (n = 1) of policies. Migraines were never offered preauthorized coverage for surgical procedures.ConclusionApproximately half of US insurance companies have a publicly available policy on surgical management of migraine or headache. Surgical treatment was seldom covered for the indication of headache and would never receive preauthorized coverage for migraine. Lack of coverage may create challenges in accessing surgical treatment. Additional prospective, controlled studies are necessary to further support the efficacy of surgical treatment.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 46 条
[1]   Greater Occipital Nerve Block for Acute Treatment of Migraine Headache: A Large Retrospective Cohort Study [J].
Allen, Sorcha M. ;
Mookadam, Farouk ;
Cha, Stephen S. ;
Freeman, John A. ;
Starling, Amaal J. ;
Mookadam, Martina .
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (02) :211-218
[2]  
American Society of Plastic Surgeons Executive Committee, 2018, SURG TREATM HEAD ASP
[3]  
[Anonymous], 2017, The State of Iowas Proposed Stopgap Measure for the Individual Health Insurance Market
[4]   OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program [J].
Aurora, Sheena K. ;
Winner, Paul ;
Freeman, Marshall C. ;
Spierings, Egilius L. ;
Heiring, Jessica O. ;
DeGryse, Ronald E. ;
VanDenburgh, Amanda M. ;
Nolan, Marissa E. ;
Turkel, Catherine C. .
HEADACHE, 2011, 51 (09) :1358-1373
[5]   Corrugator superciliaris muscle excision for tension and migraine headaches [J].
Bearden, WH ;
Anderson, RL .
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2005, 21 (06) :418-422
[6]   Botulinum Toxin in the Treatment of Headache [J].
Becker, Werner J. .
TOXINS, 2020, 12 (12)
[7]   Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden [J].
Bigal, Marcelo ;
Rapoport, Alan ;
Aurora, Sheena ;
Sheftell, Fred ;
Tepper, Stewart ;
Dahlof, Carl .
HEADACHE, 2007, 47 (04) :475-479
[8]  
Centers for Medicare & Medicaid Services, 2013, MED PROGR REV PROC M
[9]   Trigger areas nerve decompression for refractory chronic migraine [J].
Chen, Guiwen ;
You, Hengxing ;
Juha, Hernesniemi ;
Lou, Bin ;
Zhong, Yuanqiang ;
Lian, Xiaowen ;
Peng, Zhitao ;
Xu, Ting ;
Yuan, Li ;
Woralux, Phusoongnern ;
Hugo, Andrade-Barazarte ;
Jianliang Chen .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 206
[10]   OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program [J].
Dodick, David W. ;
Turkel, Catherine C. ;
DeGryse, Ronald E. ;
Aurora, Sheena K. ;
Silberstein, Stephen D. ;
Lipton, Richard B. ;
Diener, Hans-Christoph ;
Brin, Mitchell F. .
HEADACHE, 2010, 50 (06) :921-936